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ABSTRACT 
HYPOTHESIS / AIMS OF STUDY 
Bladder pain syndrome (BPS) is a poorly understood bladder condition. According to the International 
Continence Society (ICS), BPS is defined as the complaint of suprapubic pain related to bladder filling, 
accompanied by other symptoms such as increased daytime and night-time frequency, in the absence of proven 
urinary infection or other obvious pathology.[1] BPS is also defined by the European Society for the Study of 
Interstitial Cystitis/Bladder Pain as pelvic pain, pressure or discomfort perceived to be related to the bladder, 
lasting for at least 6 months, and accompanied by at least one other urinary symptom.[2]  
 
There is currently no definitive cure for BPS but a large number of treatments which aim to alleviate symptoms 
are employed with limited evidence. Previous research is hampered by its focus on numerous pairwise 
comparisons, which makes it difficult to identify the most effective treatments. This study aimed to bring 
together evidence for all available treatments that have been assessed in randomised controlled trials (RCT) by 
means of a network meta-analysis (NMA), which allow simultaneous comparisons of multiple interventions. 
 
STUDY DESIGN, MATERIALS AND METHODS 
We performed a NMA based on a systematic review of RCT of interventions for BPS in adults. RCTs were 
identified from existing Cochrane reviews and literature searches based on the Cochrane Incontinence Group 
Specialised Register, which contains trials identified from the Cochrane Central Register of Controlled Trials 
(CENTRAL), MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, ClinicalTrials.gov, WHO 
ICTRP and hand-searching of journals and conference proceedings. Searches were performed on 3 October 
2017. We also perused the reference lists of relevant identified articles. We sought any intervention 
(conservative, pharmacological or surgical) which aims to alleviate symptoms in adults with BPS, interstitial 
cystitis (IC) or painful bladder syndrome, accepting the various clinical terms used to identify this clinical 
condition in the literature. Urethral syndrome was excluded. Valid comparators were placebo, sham, control or 
another treatment. Primary outcomes were patient-reported improvement, pain, frequency and nocturia at 12 
months. Secondary outcomes included Interstitial Cystitis Symptom Index (ICSI), Interstitial Cystitis Problem 
Index (ICPI), functional bladder capacity and adverse events. Risk of bias of the included studies was assessed 
using the Cochrane risk of bias tool for RCTs. For each outcome random effects NMA models were fitted using 
WinBUGS 1.4. Three chains were used and models were run with a burn-in of 20,000 iterations and then for a 
sample of 30,000 iterations. Results for each treatment category were monitored versus control. 
 
RESULTS 
The review included 81 RCTs. Most included studies had small sample sizes (<50) with a short follow-up. Only 
six studies had a follow-up of 12 months or longer. Sample sizes ranged from 10 to 369 participants, with a 
median of 38. Follow up time ranged from 0 to 27 months, with a median of 3 months.   
 
Included studies assessed 65 different active treatments, either alone or in combination. To simplify, these were 
grouped into 31 active treatment categories by mode of action, following treatment descriptions for BPS/IC by 
the 6th International Consultation on Incontinence wherever possible.[3] Included studies were of moderate to 
low quality with three-quarters of included studies being assessed as having unclear or high risk of bias on most 
bias domains. Reporting quality of existing trials was also generally poor. For example, the number of patients 
with available data and the definition of outcome measures were not consistently reported across studies.   
 
Full results of the NMA will be available shortly, but provisional results for the proportion of patients cured are 
available. A network of 42 RCTs and 20 treatment categories was evaluated, but 13 treatment categories were 
represented by just one or two RCTs and 95% credible intervals were generally wide. There was evidence that 
three pharmacological treatment categories (anti-depressants, immune modulators, PDE5 inhibitors), one 
surgical category (neuromuscular blockade) and one conservative therapy (behavioural therapy) were effective 
versus control. Adverse events appear uncommon in most interventions assessed. Data on long-term outcomes 
were limited. 
 
INTERPRETATION OF RESULTS 
Some interventions appear to be more effective than others. However, there is considerable uncertainty around 
the estimates of effect. Longevity of treatment is unclear. 
 
CONCLUDING MESSAGE 
To the best of our knowledge, this is the largest NMA conducted to assess the effects of different interventions 
for the treatment of BPS. The number and size of available RCTs for each treatment category was small and 
there was a lack of clear evidence for the majority of treatments assessed, which rendered it difficult to draw 
firm conclusions. Larger, more focused trials are needed to improve the current evidence base.  
